Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. Issue 6 (8th June 2021)
- Record Type:
- Journal Article
- Title:
- Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. Issue 6 (8th June 2021)
- Main Title:
- Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
- Authors:
- Niogret, Julie
Berger, Hélène
Rebe, Cédric
Mary, Romain
Ballot, Elise
Truntzer, Caroline
Thibaudin, Marion
Derangère, Valentin
Hibos, Christophe
Hampe, Léa
Rageot, David
Accogli, Théo
Joubert, Philippe
Routy, Bertrand
Harker, James
Vegran, Frederique
Ghiringhelli, Francois
Chalmin, Fanny - Abstract:
- Abstract : Background: T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure. Methods: In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts. Results: In this study, we show that Tfh exert an antitumor immune effect in a CD8 + -dependent manner. Tfh produce interleukin-21, which sustains proliferation, viability, cytokine production and cytotoxic functions of exhausted T cells. The presence of Tfh is required for efficacy of antiprogrammed cell death ligand-1 therapy. Tfh accumulate in the tumor bed and draining lymph nodes in different mouse cancer models. This recruitment is due to the capacity of transforming growth factor β to drive Chemokine (C-X-C motif) Ligand 13 expression, a chemoattractant of Tfh, byAbstract : Background: T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure. Methods: In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts. Results: In this study, we show that Tfh exert an antitumor immune effect in a CD8 + -dependent manner. Tfh produce interleukin-21, which sustains proliferation, viability, cytokine production and cytotoxic functions of exhausted T cells. The presence of Tfh is required for efficacy of antiprogrammed cell death ligand-1 therapy. Tfh accumulate in the tumor bed and draining lymph nodes in different mouse cancer models. This recruitment is due to the capacity of transforming growth factor β to drive Chemokine (C-X-C motif) Ligand 13 expression, a chemoattractant of Tfh, by intratumor CD8 + T cells. Accumulation of Tfh and exhausted CD8 + T cells predicts cancer outcome in various cancer types. In patients treated with anti-programmed cell death-1 mAb, accumulation of Tfh and CD8 + at the tumor site is associated with outcome. Conclusion: This study provides evidence that CD8 + /Tfh crosstalk is important in shaping antitumor immune response generated by immunotherapy. … (more)
- Is Part Of:
- Journal for immunotherapy of cancer. Volume 9:Issue 6(2021)
- Journal:
- Journal for immunotherapy of cancer
- Issue:
- Volume 9:Issue 6(2021)
- Issue Display:
- Volume 9, Issue 6 (2021)
- Year:
- 2021
- Volume:
- 9
- Issue:
- 6
- Issue Sort Value:
- 2021-0009-0006-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-06-08
- Subjects:
- CD8-positive T-lymphocytes -- immunotherapy -- programmed cell death 1 receptor
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105 - Journal URLs:
- http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1136/jitc-2020-002157 ↗
- Languages:
- English
- ISSNs:
- 2051-1426
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17210.xml